Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.
Jan P. Nicolay, MD, PhD
Advertisement
Articles by Jan P. Nicolay, MD, PhD
Jan P. Nicolay, MD, PhD, explains why some patients stop responding to mogamulizumab comes down to the tumor shedding its target and new survival mechanisms the cell switches on.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
3
Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome
4
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
5